Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Sibbing

Showing results (11-20 of 200) with videos related to

Pageof 20
Sort By:
Handbook of Experimental Pharmacology|August 25, 2012
Thienopyridines and other ADP-receptor antagonistsIsabell Bernlochner, Dirk Sibbing
Thrombosis and Haemostasis|May 8, 2015
ATLANTIC: another reason to investigate the disconnect between stent thrombosis and mortality?Daniel Aradi, Dirk Sibbing
JACC. Cardiovascular Interventions|August 20, 2016
Smoking and Clopidogrel Response Revisited: Hemoglobin Levels Explaining the Smoker's ParadoxDirk Sibbing, Lisa Gross
Korean Circulation Journal|September 22, 2018
De-Escalation of P2Y12 Receptor Inhibitor Therapy after Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary InterventionDanny Kupka, Dirk Sibbing
Thrombosis and Haemostasis|February 19, 2016
Diplopia on vorapaxar: An unexpected side effect emerging only at second glanceLisa Gross, Dirk Sibbing
Expert Opinion on Drug Metabolism & Toxicology|January 18, 2018
P2Y<sub>12</sub> receptor inhibitors: an evolution in drug design to prevent arterial thrombosisDanny Kupka, Dirk Sibbing
JACC. Cardiovascular Interventions|February 19, 2021
Ticagrelor Monotherapy After Coronary Stenting: Like a Twilight Through the Looking GlassDirk Sibbing, Salvatore Cassese
Lancet (London, England)|September 2, 2016
Antiplatelet strategies in elderly people: still a long way to goDirk Sibbing, Steffen Massberg
Thrombosis and Haemostasis|March 24, 2017
Mortality and cancer risk on long-term antiplatelet treatment: What is known and what we still don't knowDirk Sibbing, Dániel Aradi
Lancet (London, England)|April 18, 2021
Guided P2Y<sub>12</sub> inhibitor therapy after percutaneous coronary interventionDirk Sibbing, Adnan Kastrati
Pageof 20

Showing results (11-20 of 200) with videos related to

Sort By:
Pageof 20
Handbook of Experimental Pharmacology|August 25, 2012
Thienopyridines and other ADP-receptor antagonistsIsabell Bernlochner, Dirk Sibbing
Thrombosis and Haemostasis|May 8, 2015
ATLANTIC: another reason to investigate the disconnect between stent thrombosis and mortality?Daniel Aradi, Dirk Sibbing
JACC. Cardiovascular Interventions|August 20, 2016
Smoking and Clopidogrel Response Revisited: Hemoglobin Levels Explaining the Smoker's ParadoxDirk Sibbing, Lisa Gross
Korean Circulation Journal|September 22, 2018
De-Escalation of P2Y12 Receptor Inhibitor Therapy after Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary InterventionDanny Kupka, Dirk Sibbing
Thrombosis and Haemostasis|February 19, 2016
Diplopia on vorapaxar: An unexpected side effect emerging only at second glanceLisa Gross, Dirk Sibbing
Expert Opinion on Drug Metabolism & Toxicology|January 18, 2018
P2Y<sub>12</sub> receptor inhibitors: an evolution in drug design to prevent arterial thrombosisDanny Kupka, Dirk Sibbing
JACC. Cardiovascular Interventions|February 19, 2021
Ticagrelor Monotherapy After Coronary Stenting: Like a Twilight Through the Looking GlassDirk Sibbing, Salvatore Cassese
Lancet (London, England)|September 2, 2016
Antiplatelet strategies in elderly people: still a long way to goDirk Sibbing, Steffen Massberg
Thrombosis and Haemostasis|March 24, 2017
Mortality and cancer risk on long-term antiplatelet treatment: What is known and what we still don't knowDirk Sibbing, Dániel Aradi
Lancet (London, England)|April 18, 2021
Guided P2Y<sub>12</sub> inhibitor therapy after percutaneous coronary interventionDirk Sibbing, Adnan Kastrati
Pageof 20